Interestingly, polycatechol promotes liquid-liquid phase separation of tau and regulates its intermolecular interactions to inhibit the formation of toxic tau aggregates, providing a conceptually innovative approach for treating AD.579. Here, MAPT is linked to Alzheimer disease.